首页> 外文OA文献 >The Safety and Tolerability of Intravenous ASA404 When Administered in Combination with Docetaxel (60 or 75 mg/m2) in Japanese Patients with Advanced or Recurrent Solid Tumors

【2h】

The Safety and Tolerability of Intravenous ASA404 When Administered in Combination with Docetaxel (60 or 75 mg/m2) in Japanese Patients with Advanced or Recurrent Solid Tumors

机译：在日本晚期或复发性实体肿瘤的日本患者中与多西紫杉醇（60或75mg / M2）组合时静脉内ASA404的安全性和耐受性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
H. Daga; T. Hida; S. Ishikawa; J. Shimizu; S. Tokunaga; Y. Horio; K. Kobayashi; K. Takeda;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The Safety and Tolerability of Intravenous ASA404 When Administered in Combination with Docetaxel (60 or 75 mg/m2) in Japanesen Patients with Advanced or Recurrent Solid Tumors [J] . Koji Takeda Japanese Journal of Clinical Oncology . 2011,第9期

机译：日本人晚期或复发性实体瘤患者与多西他赛（60或75 mg / m2）联合使用时静脉注射ASA404的安全性和耐受性
2. The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m(2)) in Japanese patients with advanced or recurrent solid tumors. [J] . Daga H, Hida T, Ishikawa S, Japanese journal of clinical oncology. . 2011,第9期

机译：在日本患有晚期或复发性实体瘤的患者中，与多西他赛（60或75 mg / m（2））联合使用时，静脉注射ASA404的安全性和耐受性。
3. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors [J] . C. S. Higano, J. Berlin, M. Gordon, Investigational New Drugs . 2015,第2期

机译：晚期实体瘤患者每周或每2周服用一次和多次静脉西奇单抗（IMC-A12）的安全性，耐受性和药代动力学，这是一种胰岛素样生长因子I受体的抑制剂
4. Therapy of Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Efficacy, Tolerability, and Safety of a New Nanofiltered Intravenous Immunoglobulin [C] . H.-H. Wolf, S. Davies, G. Smith, European Haematology Association . 2002

机译：慢性免疫血小板减少症患者的治疗患者（ITP）：一种新的纳米过滤静脉内免疫球蛋白的疗效，耐受性和安全性
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. An open-label dose-escalation safety and pharmacokinetics phase I study of ombrabulin a vascular disrupting agent administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors [O] . H. Murakami, T. Kurata, Y. Onozawa, -1

机译：一项开放性剂量递增安全性和药代动力学I期研究ombrabulin（一种血管破裂剂）每3周对日本晚期实体瘤患者进行30分钟静脉输注
7. Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer [O] . Takashi Seto, Fumihiko Hirai, Hideo Saka, 2017

机译：Selumetinib作为单一疗法的安全性和耐受性，或与多西紫杉醇结合为二线治疗，在日本患有先进的固体恶性肿瘤或非小细胞肺癌患者中

The Safety and Tolerability of Intravenous ASA404 When Administered in Combination with Docetaxel (60 or 75 mg/m2) in Japanese Patients with Advanced or Recurrent Solid Tumors

著录项

引文网络

相似文献

相关主题

期刊订阅